PCA3 and prostate cancer: The PCA3-Cre-PSEBC-ITSTA system, which is based on combinational activation of two prostate cancer gene promoters, has the ability to study dynamic and quantitative antiandrogen single-cell response from urine and primary cancer tissues harvested from PCa patients.